{"schema_version":"1","generated_at":"2026-11-01T11:23:44.270Z","data_as_of":null,"url":"https://www.findmykol.com/kol/tahamtan-ahmadi","json_url":"https://www.findmykol.com/kol/tahamtan-ahmadi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"tahamtan-ahmadi","name":"Tahamtan Ahmadi","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Genmab","institution_url":"https://www.findmykol.com/institution/genmab","city":"Philadelphia","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1902090475","orcid":"0009-0007-5031-3792","openalex":"A5077388722"},"summary":"Tahamtan Ahmadi is an Oncology physician affiliated with Genmab. OpenAlex indexes 189 publications with 15,890 citations (h-index 42). By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the FindMyKOL directory.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":189,"cited_by_count":15890,"h_index":42,"latest_activity_year":2025,"citation_standing":{"top_percent":10,"cohort":"Hematology / Oncology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","year":2025,"journal":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-024-03485-7","status":"verified"},{"title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","year":2024,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(24)00166-2","status":"verified"},{"title":"Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma","year":2024,"journal":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/nejmoa2409029","status":"verified"},{"title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","year":2023,"journal":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/nejmoa2312054","status":"verified"},{"title":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","year":2023,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.22.00940","status":"verified"}],"source":"works"},"contact":{"address_1":"3400 SPRUCE ST","address_2":"1 MALONEY","city":"Philadelphia","state":"PA","zip":"191044206","phone":"215-662-3681","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1902090475","source":"identity"},"similar":[{"name":"Theo S. Plantinga","slug":"theo-plantinga","institution":"Genmab","url":"https://www.findmykol.com/kol/theo-plantinga","json_url":"https://www.findmykol.com/kol/theo-plantinga/profile.json"},{"name":"Christopher W. Chiu","slug":"christopher-chiu-us","institution":"Genmab","url":"https://www.findmykol.com/kol/christopher-chiu-us","json_url":"https://www.findmykol.com/kol/christopher-chiu-us/profile.json"},{"name":"Andreea Ioan‐Facsinay","slug":"andreea-ioanfacsinay","institution":"Genmab","url":"https://www.findmykol.com/kol/andreea-ioanfacsinay","json_url":"https://www.findmykol.com/kol/andreea-ioanfacsinay/profile.json"},{"name":"Kristel Kemper","slug":"kristel-kemper","institution":"Genmab","url":"https://www.findmykol.com/kol/kristel-kemper","json_url":"https://www.findmykol.com/kol/kristel-kemper/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2008-02-25","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"}},"methodology_url":"https://www.findmykol.com/about#methodology"}